Category: Blog

Retatrutide 24 Percent Weight Loss — Clinical Evidence

Retatrutide trials show up to 24 percent weight loss at 48 weeks, surpassing all prior GLP-1 medications through triple receptor activation.

Survodutide vs Tirzepatide Research — What Clinical Data

Survodutide vs tirzepatide research reveals both are dual-receptor agonists, but survodutide targets glucagon receptors while tirzepatide focuses on

Tirzepatide Plateau Research — What Studies Reveal

Tirzepatide plateau research shows 15–25% of patients experience weight stagnation at 16–24 weeks despite continued dosing. Here’s what the clinical data

Survodutide MASH Phase 3 — Study Results & Timeline

Survodutide MASH Phase 3 trials showed 83% NASH resolution at 48 weeks with dual GLP-1/glucagon action—here’s what the 2026 data reveals about liver

Mazdutide Asian Population Research — Key Findings

Mazdutide Asian population research shows superior metabolic outcomes in East Asian cohorts, with 22.8% mean weight reduction and enhanced insulin

Orforglipron ATTAIN Trial — Results and Implications

The orforglipron ATTAIN trial demonstrated 14.7% mean weight loss at 36 weeks with once-daily oral dosing, marking a significant shift in GLP-1 therapy

BPC-157 FDA 503A Removal — What Researchers Need to Know

BPC-157 was removed from FDA 503A compounding in December 2022 due to lack of clinical data, not safety concerns — here’s what changed.

Cagrilintide Cagrisemab — Dual Amylin-PYY Mechanism

Cagrilintide cagrisemab combines dual amylin and PYY3-36 receptor agonism to slow gastric emptying and extend satiety signaling by 4–6 hours beyond

First Oral GLP-1 Pill Research — What Studies Show

First oral GLP-1 pill research shows orforglipron achieves 15% weight loss at 36 weeks with 10–30mg doses — here’s what Phase 3 trials reveal about

BPC-157 Compounding Pharmacy — Quality and Safety Explained

BPC-157 compounding pharmacy facilities prepare research-grade peptides under strict regulatory oversight — here’s what distinguishes legitimate suppliers